PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
43.51
+0.30 (+0.69%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close43.21
Open43.10
Bid43.49 x 3000
Ask0.00 x 1100
Day's Range42.91 - 43.78
52 Week Range33.20 - 45.81
Volume23,343,969
Avg. Volume21,864,193
Market Cap251.508B
Beta (3Y Monthly)0.73
PE Ratio (TTM)10.99
EPS (TTM)3.96
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.36 (3.07%)
Ex-Dividend Date2018-11-08
1y Target Est43.79
Trade prices are not sourced from all markets
  • The Wall Street Journal14 hours ago

    [$$] Pfizer to Raise Prices on 41 Drugs in January

    Pfizer Inc. plans to resume its practice of raising drug prices early next year after bowing to pressure from President Trump over the summer when the company rolled back some increases. Pfizer, among the world’s biggest drugmakers by sales, won’t be raising prices as much as it has in past years. It said it would raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January.

  • Reuters16 hours ago

    Pfizer to raise US drug prices in January after previously backing down

    Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump. Pfizer said it would raise the list price of most of the drugs by 5 percent, while prices for three will rise by 3 percent, and the price of one by 9 percent, all effective Jan. 15. Pfizer said it does not expect the price increases to boost its revenue in the United States next year as it believes that rebates to insurance companies and pharmacy benefit managers (PBMs) will offset them.

  • Pfizer to raise drug prices in January
    American City Business Journals17 hours ago

    Pfizer to raise drug prices in January

    Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10 percent of its portfolio, in January. According to The Wall Street Journal, citing an unnamed source, most of the planned increases will be 5 percent, while three of the drugs’ list prices will go up by 3 percent. One of the drug prices will go up by 9 percent, the report continued.

  • MarketWatch17 hours ago

    Pfizer to raise prices on 41 drugs: report

    Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January, The Wall Street Journal reported Friday, citing a person familiar with the matter. Most of the increases will be around 5% and would take effect Jan. 15, the person said, according to the WSJ. Pfizer rolled back some increases in July under criticism from President Donald Trump, but earlier this month Chief Executive Ian Read said Pfizer was likely to go back to price hikes in January. Shares of Pfizer rose 0.1% in the extended session Friday after ending the regular trading day up 0.7%.

  • TheStreet.com17 hours ago

    Pfizer Plans Price Hikes for 41 Drugs Next Year

    said Friday, Nov. 16, it plans to increase list prices for 41 of its drugs effective Jan. 15. The plan was first reported by The Wall Street Journal. "The only exceptions are three products that have a 3% increase and one product that is increasing 9% due to the completion of two extensive development programs that have led to the recent FDA approvals of two new medical uses that meet unmet patient needs," Pfizer said.

  • CNBC18 hours ago

    Pfizer to raise prices on 41 prescription drugs next year despite pressure from Trump

    Pfizer will raise list prices on 41 prescription drugs in January. Pfizer this summer deferred planned price increases after President Donald Trump criticized the drug giant. Trump said Pfizer and other drugmakers "should be ashamed" of themselves.

  • AstraZeneca Shows It Can Still Take Some Knocks
    Bloombergyesterday

    AstraZeneca Shows It Can Still Take Some Knocks

    On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.

  • Financial Timesyesterday

    [$$] Pfizer to raise prices for 41 drugs despite Trump criticism

    Pfizer said it would increase the price of 41 products in its drug portfolio, just four months after having initially put off those plans amid heavy criticism from US President Donald Trump. — after Mr Trump said it should be “ashamed” of the move and that it and other rivals were “taking advantage of poor people”. Effective January 15, 2019, prices for 37 of the products will rise by 5 per cent, while three products will see prices rise by 3 per cent, and one by 9 per cent.

  • Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
    Zacks2 days ago

    Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

    Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

  • Why Pfizer Is Up 19% in 2018 So Far
    Motley Fool2 days ago

    Why Pfizer Is Up 19% in 2018 So Far

    Here's what has investors revved up about the big pharma stock.

  • 3 Dividend Stocks Ideal for Retirees
    Motley Fool2 days ago

    3 Dividend Stocks Ideal for Retirees

    If you're looking for a solid income stream to complement Social Security and saving, check out these three great dividend stocks.

  • Here's Why Sangamo Therapeutics Lost 12% Today
    Motley Fool3 days ago

    Here's Why Sangamo Therapeutics Lost 12% Today

    Wall Street is growing increasingly concerned about the progress the company's making with a gene therapy for hemophilia A.

  • Reuters3 days ago

    Pfizer loses drug patent fight in UK top court, may face claims

    Pfizer (PFE.N) lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan (AGN.N), and Mylan (MYL.O). Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

  • Pfizer loses drug patent fight in UK top court, may face claims
    Reuters3 days ago

    Pfizer loses drug patent fight in UK top court, may face claims

    Pfizer lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan, and Mylan. Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

  • 7 Highest-Yielding Dow Dividend Stocks
    Kiplinger3 days ago

    7 Highest-Yielding Dow Dividend Stocks

    Volatile markets like today's are a good time to remind long-term investors of the virtues of big, stable dividend stocks like those found in the Dow Jones Industrial Average. It's hard to beat blue-chip dividend stocks when it comes to long-term performance. Witness the highest-yielding Dow dividend stocks. Although not every name is necessarily a buy at current levels, each and every one has distinguished itself over the decades. Note that many of the highest-yielding Dow dividend payers rank among the best equity investments of all time. In several instances, these stocks remain top picks among Wall Street analysts, mutual fund managers and hedge fund managers today. Big, healthy balance sheets and reliable and rising dividends also tend to make the highest-yielding dividend stocks in the Dow Jones less volatile than the broader market. That can help income investors sleep better at night. Here are the highest-yielding Dow dividend stocks, with yields ranging from just more than 3% to over 5%. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond

  • Reuters4 days ago

    Walmart, Home Depot adopt health insurer tactic in drug copay battle

    Walmart and Home Depot , two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards for everything from multiple sclerosis treatments to widely-used rheumatoid arthritis medications sold through a specialty pharmacy.

  • Pfizer (PFE) Stock Moves -0.38%: What You Should Know
    Zacks5 days ago

    Pfizer (PFE) Stock Moves -0.38%: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.11, marking a -0.38% move from the previous day.

  • These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
    Investor's Business Daily5 days ago

    These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece

    Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.

  • Corbus Pharmaceuticals Holdings’ Performance in 2018
    Market Realist5 days ago

    Corbus Pharmaceuticals Holdings’ Performance in 2018

    Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.

  • How Nektar Performed in the Third Quarter
    Market Realist5 days ago

    How Nektar Performed in the Third Quarter

    Nektar Therapeutics (NKTR) released its third-quarter results on November 8. On November 6, Nektar announced a clinical oncology collaboration with Pfizer (PFE) to evaluate the combination of NKTR-214 with avelumab and talazoparib in different cancer areas. Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the comparable period of 2017.

  • Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)
    Insider Monkey6 days ago

    Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)

    The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]

  • Better Buy: Amgen Inc. vs. Pfizer Inc.
    Motley Fool6 days ago

    Better Buy: Amgen Inc. vs. Pfizer Inc.

    Which big drugmaker is the better pick for long-term investors?

  • Final Trades: Virtu, JPMorgan & Pfizer
    CNBC Videos21 hours ago

    Final Trades: Virtu, JPMorgan & Pfizer

    The "Halftime Report" traders give their top stocks to watch for the second half.